Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (111-120 of 238) with videos related to

Pageof 24
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2014
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumorsPasi A Jänne, Roger B Cohen, A Douglas Laird, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 1998
Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injuryF Galbiati, D Volonte, O Gil, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 12, 2013
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Hiromichi Ebi, Carlotta Costa, Anthony C Faber, et al.
Cancer Research|May 4, 2012
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and METLu Xu, Eiki Kikuchi, Chunxiao Xu, et al.
Molecular and Cellular Biology|December 22, 1998
Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivoE Gómez Lahoz, N J Liegeois, P Zhang, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
The Journal of Biological Chemistry|August 28, 1999
Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complexI Parolini, M Sargiacomo, F Galbiati, et al.
Nature Genetics|February 2, 2000
Gene-target recognition among members of the myc superfamily and implications for oncogenesisR C O'Hagan, N Schreiber-Agus, K Chen, et al.
Oncogene|February 2, 2010
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorD Ercan, K Zejnullahu, K Yonesaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancerShuji Ogino, Katsuhiko Nosho, Gregory J Kirkner, et al.
Pageof 24

Showing results (111-120 of 238) with videos related to

Sort By:
Pageof 24
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2014
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumorsPasi A Jänne, Roger B Cohen, A Douglas Laird, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 1998
Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injuryF Galbiati, D Volonte, O Gil, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 12, 2013
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Hiromichi Ebi, Carlotta Costa, Anthony C Faber, et al.
Cancer Research|May 4, 2012
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and METLu Xu, Eiki Kikuchi, Chunxiao Xu, et al.
Molecular and Cellular Biology|December 22, 1998
Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivoE Gómez Lahoz, N J Liegeois, P Zhang, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
The Journal of Biological Chemistry|August 28, 1999
Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complexI Parolini, M Sargiacomo, F Galbiati, et al.
Nature Genetics|February 2, 2000
Gene-target recognition among members of the myc superfamily and implications for oncogenesisR C O'Hagan, N Schreiber-Agus, K Chen, et al.
Oncogene|February 2, 2010
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorD Ercan, K Zejnullahu, K Yonesaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancerShuji Ogino, Katsuhiko Nosho, Gregory J Kirkner, et al.
Pageof 24